Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs in mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Wenhua, Wu, Xuan, Fang, Wenfeng, Zhao, Yuanyuan, Yang, Yunpeng, Hu, Zhihuang, Xue, Cong, Zhang, Jing, Zhang, Jianwei, Ma, Yuxiang, Zhou, Ting, Yan, Yue, Hou, Xue, Qin, Tao, Dinglin, Xiaoxiao, Tian, Ying, Huang, Peiyu, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922700/
https://www.ncbi.nlm.nih.gov/pubmed/24533047
http://dx.doi.org/10.1371/journal.pone.0085245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922700/
https://www.ncbi.nlm.nih.gov/pubmed/24533047
http://dx.doi.org/10.1371/journal.pone.0085245

Ejemplares similares